Pegvisomant Patent Expiration

Pegvisomant is used for treating acromegaly in patients who have not responded well to surgery, radiation therapy, or medical therapies. It was first introduced by Pharmacia And Upjohn Co in its drug Somavert on Mar 25, 2003. 2 different companies have introduced drugs containing Pegvisomant.


Pegvisomant Patents

Given below is the list of patents protecting Pegvisomant, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Somavert US5849535 Human growth hormone variants Mar 25, 2017

(Expired)

Pharmacia And Upjohn
Somavert US5849535 Human growth hormone variants Mar 25, 2017

(Expired)

Pharmacia
Somavert US6057292 Method for inhibiting growth hormone action Sep 21, 2015

(Expired)

Pharmacia
Somavert US6057292 Method for inhibiting growth hormone action Sep 21, 2015

(Expired)

Pharmacia And Upjohn



Pegvisomant's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List